VNRX - Public offerings

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. T

Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025.  Volition management will host a conference call tomorrow, November 14 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 efforts for Volition focused on commercializing our groundbreaking Nu.Q® platform in the h

HENDERSON, Nev., Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of its common stock. The public offering price of for each share of common stock and an accompanying warrant to purchase one share of common stock is $0.52 per set of securities (with $0.01 allocated to the warrant). Each warrant has an exercise price per share of $0.60, is exercisable immediately upon issuance, and expires five years from the issuance date. In connection with the offering, Volit

HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and warrants offered in the offering at the public offering price, less underwriting discounts and commissions. All of the securities in the offering are being offered by Volition. The final terms of the proposed offering will depend on ma

Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter ended June 30, 2025. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.   Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground

HENDERSON, Nev., Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i)  156,250 shares of its common stock to certain directors and executive officers of the Company (collectively, the "Insiders") at an offering price of $0.64 per share, and (ii) 1,734,375 shares of its common stock, together with common stock purchase warrants to purchase up to 1,734,375 shares of common stock (individually, a "Warrant" and collectively, the "Warrants"), to certain other existing stockholders of the Company at a combined offering

Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024.  Volition management will host a conference call today, March 31 at 4:30 p.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.   Highlights Sold approximately 120,000 Nu.Q® Vet Cancer Tests in 2024.Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in over

Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev., March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive agreements for the purchase and sale of (i) 2,363,636 shares of its common stock to certain directors, executive officers, and certain existing stockholders of the Company (collectively, the "Insiders") at an offering price of $0.55 per share, and (ii) 1,739,087 shares of its common stock, together with common stock purchase warrants

Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev, Dec. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 445,648 shares of its common stock to certain directors and executive officers of the Company (the "Insiders") at an offering price of $0.5722 per share, and (ii) 2,857,389 shares of its common stock, together with common stock purchase warrants, composed of Form A warrants to purchase up to 2,

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the second quarter of 2024. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights in the first half of 2024 Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 17 countries worldwide.Sold over 60,000 Nu.Q® Vet Cancer Tests in the fi

$7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev., Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its common stock (or common stock equivalents in lieu thereof) and milestone-linked warrants, composed of series A warrants to purchase up to 12,727,273  shares of common stock and series B warrants to purchase up to 12,727,273 shares of common stock, at an offering price of $0.55 per shar

Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2023. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "I am delighted to report that we submitted a Breakthrough Device Designation Request to the FDA in June for our Nu.Q® technology in relation to sepsis. This was a milestone moment in our company's history and for

HENDERSON, Nev., June 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to Volition from the offering to approximately $19.0 million, before deducting underwriting commissions and other offering expenses payable by Volition. All of the shares of common stock sold in the offering, including the over-allotment, were offered by Volition. The exercise of the over-allotment option closed on June 23

HENDERSON, Nev., June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million, before deducting underwriting commissions and other offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes,

HENDERSON, Nev., June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $16.5 million. In addition, Volition has granted the underwriters a 30-day option to purchase up to an additional 1,950,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cove

HENDERSON, Nev., May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are being offered by Volition. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whet

Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2023. Volition management will host a conference call tomorrow, May 11 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "It has been a phenomenal start to the year, with the launch of our Nu.Q® Vet Cancer Test through IDEXX's reference laboratory network. It is also available as the Heska Nu.Q® Canine Cancer Screen and Monitor test throug

Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time Executed global licensing and supply agreement with Heska Corporation ("Heska") to distribute Nu.Q® Vet Cancer Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones. Volition will also receive ongoing additional revenue from the use by Heska of  Volition's key components and reference laboratory kits.Executed a global supply agreement with IDEXX Laboratories, Inc. ("IDEXX"), a global leader in pet healthcare innovation, as a provider of the Nu.Q® Vet Cancer Test through its reference l

HENDERSON, Nev., March 06, 2023 (GLOBE NEWSWIRE) -- VolitionRx Limited (NYSE:VNRX), a multi-national epigenetics company, today announced that Scott Powell, Vice President of Investor Relations at VolitionRx Limited and Chief Investment Officer of Volition America, will present live at the Life Science Investor Forum, hosted by VirtualInvestorConferences.com, on March 9th, 2023. DATE: March 9th, 2023TIME: 09:30 am ETLINK: https://bit.ly/3IoXpvPAvailable for 1x1 meetings: March 13 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived

HENDERSON, Nevada, Feb. 22, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 4,945,000 shares of its common stock, including the exercise in full of the underwriter's overallotment option, at a public offering price of $1.75 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other offering expenses payable by Volition, were approximately $8.7 million. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds from the offering for res

HENDERSON, Nev., Feb. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $7.525 million. In addition, Volition has granted the underwriter a 30-day option to purchase up to an additional 645,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover

HENDERSON, Nev., Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are being offered by Volition. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whet

Conference call to discuss financial and operational results scheduled for Tuesday, November 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2022. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "I am delighted with the progress we have made across many of our Nu.Q® pillars as we move forward from purely a research and development company to a commercial company with a wide range of innovative prod

Conference call to discuss financial and operational results scheduled for Thursday, August 11, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada, Aug. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2022. Volition management will host a conference call tomorrow, August 11 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "I am delighted with the progress we are making, and in particular could not be prouder of the team's achievement in securing a CE Mark for Nu.Q® NETs in Europe and in announcing new clinical studies for NETosis

HENDERSON, Nev., Aug. 2, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the exercise in full of the underwriter's overallotment option, at a public offering price of $2.00 per share.  The gross proceeds to Volition from the offering were $6.9 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds from the offering for resear

HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the offering a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover

HENDERSON, Nev., July 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock.  All of the shares of common stock are being offered by Volition.  In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.  The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering

Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio Initiated production of product components at scale at the Company's Silver One facility Published three clinical papers Continued focus on product launches and licensing in both the human and veterinary spaces AUSTIN, Texas, May 11, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2021. Volition management will host a conference call tomorrow, May 12 at 8:00 a.m. U.S. Eastern Time to

Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial for Non-Hodgkin's Lymphoma Expanded research program for the use of Nu.Q® technology in NETosis (COVID-19 and sepsis) Strengthened intellectual property portfolio Purchased and opened first production facility Strongest-ever cash position following a public offering in February 2021 AUSTIN, Texas, March 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year ended December 31, 2020. Voli

AUSTIN, Texas, Feb. 12, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its underwritten public offering of 3,809,524 shares of its common stock (the "Offering") for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares in the Offering were sold by Volition. In addition, Volition has granted the underwrite

AUSTIN, Texas, Feb. 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced the pricing of its underwritten public offering of 3,809,524 shares of its common stock (the "Offering") for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition.  All of the shares to be sold in the Offering will be sold by Volition, subject to customary closing conditions

AUSTIN, Texas, Feb. 9, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it is commencing an underwritten public offering of its common stock (the "Offering").  All of the shares to be sold in the Offering will be sold by Volition, subject to customary closing conditions. In addition, Volition intends to grant the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of shares of its commo